Phio Pharmaceuticals Open enrollment in Phase 1b Trial of PH-762 for the Treatment of Advanced Melanoma

Phio Pharmaceuticals Corp. PHIO has started enrolling patients in the Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma.

The phase 1b study will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma.

Dr. Gerrit Dispersyn, President and CEO of Phio, said, “We are excited to advance our first-in-human clinical trial for our lead program, PH-762, to treat patients with melanoma. The start of this clinical study marks a significant milestone for Phio and our INTASYL therapeutic platform”.

The company noted that a dose escalation of PH-762 monotherapy will feature in the course of the clinical study that is designed to allow for a data driven evaluation of the recommended Phase 2 dose.

Phio Pharmaceuticals is currently trading down 10 percent at $1.115.

Posted In: BiotechNewsPenny StocksHealth CareFDAGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...